177Lu-PSMA-617 for metastatic prostate cancer: aiming for the …
Sep 28, 2024 · 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer …
Final overall survival and safety analyses of the phase III PSMAfore ...
Abstract Background: In PSMAfore, [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic …
ASCO 2025: Lutetium-177-PSMA-617 in Oligo-Metastatic …
Jun 3, 2025 · Dr. Privé concluded as follows: PSMA radioligand therapy is a promising novel treatment option for patients with oligorecurrent, hormone-sensitive prostate cancer. In this …
Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage ...
May 18, 2025 · Pluvicto works by targeting prostate cancer cells, particularly in metastatic castration-resistant prostate cancer (mCRPC), where PSMA is present in high amounts. After …
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA …
5 days ago · [177Lu]Lu-PSMA-617 radiopharmaceutical therapy improves survival and quality of life in patients with metastatic castration-resistant prostate cancer. We assessed whether …
Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate …
May 28, 2025 · 5009Background: [177Lu]Lu-PSMA-617 (Pluvicto) is a novel treatment for patients with metastatic castration resistant prostate cancer. In a phase 1 dosimetry study, we …
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Jun 23, 2021 · We conducted an international, open-label, phase 3 trial evaluating 177 Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with …
Lutetium-177 shows significant rPFS benefit for metastatic prostate cancer
Jan 20, 2024 · Mayo Clinic's multidisciplinary prostate cancer team has been at the forefront of offering these new options to patients with metastatic prostate cancer, administering the …
Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in ...
May 29, 2025 · [177Lu]Lu-PSMA-RLT shows promising efficacy and an acceptable safety profile for metastatic castration-resistant prostate cancer with extensive bone metastases. This study …
Emerging Evidence-Based Treatment Strategies in Metastatic …
4 days ago · Morris MJ et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant …